Personalized Medicine for Pancreatic Cancer: A Step in the Right Direction

Gastroenterology

Volumn 136, Issue 1, 2009, Pages 43-45

  Ko, Andrew H ^a   Tempero, Margaret A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DEOXYRIBONUCLEOTIDE 5' DIPHOSPHATE; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; NUCLEOSIDE TRANSPORTER; PROTEIN SUBUNIT; PYRIMIDINE; PYROPHOSPHATE; RIBONUCLEOTIDE REDUCTASE; THYMIDINE PHOSPHATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CARRIER PROTEIN; CIF NUCLEOSIDE TRANSPORTER; DEOXYCYTIDINE; DRUG DERIVATIVE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; SLC29A1 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIVISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DNA SYNTHESIS; DRUG UPTAKE; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; CHEMISTRY; NOTE; PANCREAS TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; HUMANS; MEMBRANE TRANSPORT PROTEINS; PANCREATIC NEOPLASMS;

EID: 59849124142     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.11.027     Document Type: Editorial

References (14)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Farrell J.J., Elsaleh H., Garcia M., et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136 (2008) 187-195
3. Kalser M.H., and Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (1985) 899-903
4. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004) 1200-1210
5. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
6. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297 (2007) 267-277
7. Neuhaus P., Riess H., Post S., et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. (abstract). J Clin Oncol 26 (2008) LBA4504
8. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
9. Javle M.M., Okazaki T., Evans D.B., et al. Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer (abstract). J Clin Oncol 26 (2008) 4501
10. Rosell R., Danenberg K.D., Alberola V., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10 (2004) 1318-1325
11. Sebastiani V., Ricci F., Rubio-Viqueira B., et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12 (2006) 2492-2497
12. Souglakos J., Boukovinas I., Taron M., et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98 (2008) 1710-1715
13. Qiu L.X., Tang Q.Y., Bai J.L., et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 123 (2008) 2384-2389
14. Soong R., Shah N., Salto-Tellez M., et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19 (2008) 915-919